T cell dynamism and immune-related adverse events
- PMID: 36868223
- DOI: 10.1016/j.ccell.2023.02.006
T cell dynamism and immune-related adverse events
Abstract
Immune-related adverse events (irAEs) are a major complication of immune checkpoint inhibitors (ICIs) and occur in an unpredictable fashion. In a Med article, Nunez et al. profile peripheral blood markers in patients treated with ICIs, identifying that dynamic changes in proliferating T cells and cytokine upregulation are associated with irAEs.
Copyright © 2023 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests D.B.J. has served on advisory boards or as a consultant for Bristol Myers Squibb (BMS), Catalyst Biopharma, Iovance, Jansen, Mallinckrodt, Merck, Mosaic ImmunoEngineering, Novartis, Oncosec, Pfizer, and Targovax and has received research funding from BMS and Incyte. J.M.B. receives research support from Genentech/Roche and Incyte Corporation, has received advisory board payments from AstraZeneca and Mallinckrodt, and is an inventor on patents regarding immunotherapy targets and biomarkers in cancer.
Comment on
-
Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors.Med. 2023 Feb 10;4(2):113-129.e7. doi: 10.1016/j.medj.2022.12.007. Epub 2023 Jan 23. Med. 2023. PMID: 36693381
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
